Abstract:OBJECTIVE:To develop human papillomavirus (HPV) 16 DNA vaccine for the treatment of HPV16 infection and its related tumors.METHODS:HPV16 oncogene E7 was modified by combined approaches including insertion and replication of specific region of E7 gene, murine codon optimization, and point-mutation at transforming regions of the E7 protein. The resulting artificial gene, named as mE7, was obtained by gene synthesis. The mE7 gene was then genetically fused to murine CD40 ligand (CD40L) by overlapping PCR to form the mE7/CD40L fusion gene. The mE7/CD40L gene was inserted into pVR1012 plasmid and then immunized C57/BL6 mice intramuscularly. The E7-specific IFN-gamma-secreting CD8+ T cells were analyzed with EIISPOT, and E7-specific antibody was measured by indirect ELISA. FACS assays were performed to analyze the activation of E7-specific Th cells. Mice were vaccinated, followed by tumor challenged or challenged before immunization. Tumor growth was observed.RESULTS:The mE7 DNA vaccine elicited an increased E7-specific antibody level (P < 0.01), E7-specific IFN-gamma-secreting CD8+ T (P < 0.01), and CD4+ T cells number (P < 0.05), compared with those of mice immunized with wE7 gene. Furthermore, the mE7/CD40L DNA vaccine elicited an increased number of E7-specific IFN-gamma secreting CD8+ T cell compared with that of mice immunized with mE7 gene (P < 0.01); however, no significant differences were found between mice immunized with the mE7 gene and mE7/CD40L fusion gene in the E7-specific antibody production and Th cell activation. In the preventive experiment, all mice received the mE7 or mE7/CD40L remained tumor-free 7 weeks after challenges with TC-1 tumor cells, while the wE7 group exhibited tumor growth within 2 weeks. In the therapeutic experiment, all the mice in the wE7 group exhibited tumor growth within 8 days, while among mice receiving the mE7 and mE7/CD40L, 30% and 45% of mice remained tumor-free after TC-1 challenge, respectively. HE staining of tumor tissues showed copious lymphocytes infiltration around tumor cells in mE7 and mE7/CD40L mice with regression of tumor growth.CONCLUSIONS:The mE7 DNA vaccine increases the E7-specific humoral and cellular immune responses, and the fusion of CD40L to mE7 gene enhances the specific immune responses and anti-tumor effects against HPV16 E7-expressing murine tumors. mE7/CD40L may therefore be a suitable and promising target for HPV16 therapeutic vaccine.

Inhibitory Effect of the HPV-16mE6Delta/mE7/TBhsp70Delta Vaccine on Oral Squamous Cell Carcinoma

Influence of Human Papillomavirus E7 Oncoprotein on Maturation and Function of Plasmacytoid Dendritic Cells in Vitro

Effects of Human Papillomavirus Type 16 E7 Protein on the Growth of Cervical Carcinoma Cells and Immuno-Escape Through the TGF-β1 Signaling Pathway

HPV DNA vaccines expressing recombinant CRT/HPV6bE7 fusion protein inhibit tumor growth and angiogenic activity]

Vaccination of Full-Length HPV16 E6 or E7 Protein Inhibits the Growth of HPV16 Associated Tumors

Immunization of Protein HPV16 E7 in Fusion with Mouse HSP70 Inhibits the Growth of TC-1 Cells in Tumor Bearing Mice.

Study of therapeutic adjuvant-free protein vaccine-HPV16Z-Hsp65-E6/E7

Human HSP70 and Modified HPV16 E7 Fusion DNA Vaccine Induces Enhanced Specific CD8+ T Cell Responses and Anti-Tumor Effects.

Enhanced Immunotherapeutic Effect of Modified HPV16 E7-pulsed Dendritic Cell Vaccine by an Adeno-Shrna-socs1 Virus

Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer

Mucosal HPV E6/E7 peptide vaccination in combination with immune checkpoint modulation induces regression of HPV+ oral cancers.

Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies

Establishment of a Cervical Cancer Model Via Inoculating SiHa Cells into Humanized Severe Combined Immunodeficient Mice.

Cervical Cancer-Associated Human Papillomavirus 16 E7 Oncoprotein Inhibits Induction of Anti-Cancer Immunity by a CD4+ T Cell Dependent Mechanism

Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study

Elimination of human papillomavirus 16-induced tumors by a mucosal rAd5 therapeutic vaccination in a pre-clinical study

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine

Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins

Linkage of Modified Human Papillomavirus Type 16 E7 to CD40 Ligand Enhances Specific CD8 + T-lymphocyte Induction and Anti-tumour Activity of DNA Vaccine

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice